The stock is still showing positive momentum due to strong ... I believe that the positive momentum will continue and that Celldex is still a buy despite recent rallies. Celldex Therapeutics Celldex is a biopharmaceutical involved in the …
NEW YORK, Nov. 22, 2017 /PRNewswire/ -- If you want a Stock Review on CALA, CLDX, CLVS, or CYTK then come …
At the end of September, CEO Anthony Marucci gave a highly anticipated corporate update at the Cantor Fitzgerald Global Healthcare Conference that caused the company's shares to gain over 22% in just two days leading up to this …
It looks like the heavy losses left bruises that the market isn't ready to forget, and the stock has yet to recover. That could change before too long. Celldex has another candidate approaching the finish line, called glemba, that is entirely …
A month has gone by since the last earnings report for Celldex Therapeutics, Inc. CLDX. Shares have lost about 4.4% in that time frame, underperforming the market. Will the recent negative trend continue leading up to the stock's next …
Celldex shares were trading down 11.5% to $2.42 on Tuesday. The stock has a 52-week trading range of $2.37 to $5.02 and a consensus analyst price target of $6.50. Shares of Bristol-Myers were last seen down 1% at $51.73, with a …
Celldex Therapeutics, Inc. CLDX is expected to report third-quarter 2016 results on Nov 3. Celldex’s performance has been encouraging with a three-quarter average positive surprise of 4.85%. In the last reported quarter, the company …
... Therapeutics Inc. (CLDX) is a biotechnology company focused on developing antibody-based combination immunotherapies for the treatment of cancer and other difficult-to-treat diseases. RTTNews had alerted readers to the …
Last week Healthcor disclosed a 5.86% stake in Celldex (CLDX) in a 13G filing. They paid around $3.30 per share on May 18th when the stock closed at $3.31. The stock currently trades at $3.70, giving Healthcor a 10+% return in less than …